Cooperative serum bactericidal activity between human antibodies to meningococcal factor H binding protein and neisserial heparin binding antigen.
A meningococcal group B vaccine containing multiple protein antigens including factor H binding protein (fHbp) and Neisserial heparin binding antigen (NHba) is in clinical development. The ability of antibodies against individual antigens to interact and augment protective immunity is unknown. We assayed human complement-mediated bactericidal activity (SBA) in stored sera from six immunized adults before and after depletion of antibodies to fHbp and/or NHba. All six subjects developed ≥ 4-fold increases in SBA titer against a test strain with fHbp in the variant 1 group with an amino acid sequence that matched the vaccine antigen (GMT <1:4 baseline, to 1:139 after 3 doses of vaccine). By adsorption 88 to >95% of the SBA was directed against fHbp. Four subjects developed ≥ 4-fold increases in SBA titer against a test strain with a heterologous fHbp variant 2 antigen and a homologous NHba amino acid sequence that matched the vaccine antigen (GMT <1:4 baseline, to 1:45). SBA was directed primarily against NHba in one subject, against fHbp in a second, while depletion of either anti-NHba or anti-fHbp antibody removed the majority of SBA in sera from two subjects. In all four subjects, depletion of both anti-fHbp and anti-NHba antibodies removed more SBA than depletion of either antibody individually. Mixing a mouse non-bactericidal anti-fHbp variant 1 antiserum with a mouse anti-NHba antiserum also augmented the anti-NHba SBA titer against this test strain. For meningococcal vaccines that target relatively sparsely exposed antigens such fHbp or NHba, non-bactericidal antibodies against individual antigens can cooperate and elicit SBA.
Center for Immunobiology and Vaccine Development, Children's Hospital Oakland Research Institute, Oakland, California, USA.
David M
DM
Vu
Tracy T
TT
Wong
Dan M
DM
Granoff
D000328:Adult; D000818:Animals; D000907:Antibodies, Bacterial / Q000276:immunology*; D000942:Antigens, Bacterial / Q000276:immunology*; D001426:Bacterial Proteins / Q000276:immunology*; D001770:Blood Bactericidal Activity; D003165:Complement System Proteins / Q000276:immunology; D005260:Female; D006801:Humans; D051379:Mice; D050296:Microbial Viability; D009345:Neisseria meningitidis / Q000276:immunology*
D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial; D001426:Bacterial Proteins; C484699:factor H-binding protein, Neisseria meningitidis; D003165:Complement System Proteins
J Clin Microbiol. 2009 Nov;47(11):3577-85
19759227
Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):3140-5
9501229
J Infect Dis. 2008 Apr 1;197(7):1053-61
18419542
Science. 2000 Mar 10;287(5459):1816-20
10710308
Infect Immun. 2007 Nov;75(11):5434-42
17664268
Clin Vaccine Immunol. 2010 Jun;17(6):919-29
20375242
Infect Immun. 1982 Jul;37(1):155-9
6809624
Vaccine. 2007 Apr 20;25(16):3075-9
17289223
Infect Immun. 1999 Mar;67(3):1267-76
10024570
Proc Natl Acad Sci U S A. 2006 Jul 18;103(29):10834-9
16825336
Infect Immun. 2008 Sep;76(9):4232-40
18591239
Vaccine. 2010 Jul 12;28(31):5023-30
20493284
J Exp Med. 2003 Mar 17;197(6):789-99
12642606
J Infect Dis. 2009 May 1;199(9):1360-8
19302008
J Infect Dis. 2003 Dec 1;188(11):1730-40
14639545
Microb Pathog. 1991 Dec;11(6):447-52
1795633
Proc Natl Acad Sci U S A. 2010 Feb 23;107(8):3770-5
20133713
Infect Immun. 2004 Apr;72(4):2088-100
15039331
J Infect Dis. 2009 Aug 1;200(3):379-89
19534597
J Infect Dis. 2007 May 15;195(10):1472-9
17436227
Clin Vaccine Immunol. 2010 Jul;17(7):1074-8
20519444
Clin Vaccine Immunol. 2009 Feb;16(2):156-62
19109451
Vaccine. 2010 Feb 25;28(9):2122-9
20044056
Vaccine. 2009 May 11;27(21):2794-803
19428890
Infect Immun. 2008 Jun;76(6):2568-75
18362128
Nature. 2009 Apr 16;458(7240):890-3
19225461
Clin Vaccine Immunol. 2009 Jun;16(6):785-91
19339487